A practical approach for PD-L1 evaluation in gastroesophageal cancer

PD-L1 is an established predictive immunohistochemical biomarker of response to immune checkpoint inhibitors. At present, PD-L1 is routinely assessed on biopsy samples of advanced gastroesophageal cancer patients before initiating first-line treatment. However, PD-L1 is still a suboptimal biomarker,...

Descripción completa

Detalles Bibliográficos
Autores principales: Angerilli, Valentina, Fassan, Matteo, Parente, Paola, Gullo, Irene, Campora, Michela, Rossi, Chiara, Sacramento, Maria Luisa, Pennelli, Gianmaria, Vanoli, Alessandro, Grillo, Federica, Mastracci, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pacini Editore srl 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462995/
https://www.ncbi.nlm.nih.gov/pubmed/36537078
http://dx.doi.org/10.32074/1591-951X-836
Descripción
Sumario:PD-L1 is an established predictive immunohistochemical biomarker of response to immune checkpoint inhibitors. At present, PD-L1 is routinely assessed on biopsy samples of advanced gastroesophageal cancer patients before initiating first-line treatment. However, PD-L1 is still a suboptimal biomarker, due to changing cut-off values and scoring systems, interobserver and interlaboratory variability. This practical illustrated review discusses the range of staining patterns of PD-L1 and the potential pitfalls and challenges that can be encountered when evaluating PD-L1, focusing on gastric and gastroesophageal adenocarcinoma (G/GEA) and esophageal squamous cell carcinoma (ESCC).

Ejemplares similares